Asian Annals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Permyos Ruengsakulrach
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arom, K. V
Right arrow Articles by Tiensuwan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arom, K. V
Right arrow Articles by Tiensuwan, M.

ORIGINAL ARTICLE

Intramyocardial Angiogenic Cell Precursors in Nonischemic Dilated Cardiomyopathy

Kitipan V Arom, PhD, Permyos Ruengsakulrach, PhD, Michael Belkin, MD1, Montip Tiensuwan, PhD2

Cardiovascular Surgery, Bangkok Heart Hospital Bangkok, Thailand
1 Sackler Faculty of Medicine, Tel-Aviv University Tel-Aviv, Israel
2 Department of Mathematics, Faculty of Science, Mahidol University Bangkok, Thailand

Kitipan V Arom, PhD, Tel: +662 3103323, Fax: +662 3103088, Email: karom{at}bangkokheart.com, Division of Cardiovascular Surgery, Bangkok Heart Hospital, 2 Soi Soonvijai 7, New Petchburi Road, Bangkok 10320, Thailand.

ABSTRACT

To determine the efficacy of intramyocardial injection of angiogenic cell precursors in nonischemic dilated cardiomyopathy, 35 patients with nonischemic dilated cardiomyopathy underwent injections of angiogenic cell precursors into the left ventricle (cell group). Seventeen patients with nonischemic dilated cardiomyopathy were matched from the heart failure database to form a control group that was treated medically. Angiogenic cell precursors were obtained from autologous blood, cultured in vitro, and injected into all free-wall areas of the left ventricle in the cell group. After these injections, New York Heart Association functional class improved significantly by 1.1 ± 0.7 classes at 284.7 ± 136.2 days, and left ventricular ejection fraction improved in 71.4% of patients (25/35); the mean increase in left ventricular ejection fraction was 4.4% ± 10.6% at 192.7 ± 135.1 days. Improved quality of life was demonstrated by better physical function, role-physical, general health, and vitality domains in a short-form health survey at the 3-month follow-up. In the control group, there were no significant improvements in left ventricular ejection fraction or New York Heart Association class which increased by 0.6 ± 0.8 classes. It was concluded that intramyocardial angiogenic cell precursor injection is probably effective in the treatment of nonischemic dilated cardiomyopathy.

Disclosures and Freedom of Investigation

Professor Michael Belkin is an advisory board member, a minor shareholder, and receives a consulting fee from TheraVitae Co. Ltd. However, the authors had full control of the study, methods used, outcome measurements, data analysis, and production of the written report.

Key Words: Adult Stem Cells • Cardiomyopathy • Dilated • Heart Failure • Hematopoietic Stem Cell Transplantation • Ventricular Dysfunction • Left

Asian Cardiovasc Thorac Ann 2009; 17:382-388
© 2009 by SAGE Publications
DOI: 10.1177/0218492309338105




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by SAGE Publications